Edition:
India

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

34.72USD
1:30am IST
Change (% chg)

$0.96 (+2.84%)
Prev Close
$33.76
Open
$33.24
Day's High
$35.11
Day's Low
$32.70
Volume
1,817,053
Avg. Vol
376,908
52-wk High
$41.57
52-wk Low
$16.71

Summary

Name Age Since Current Position

Mark Timney

54 2018 Chief Executive Officer, Director

Christopher Visioli

43 2018 Chief Financial Officer, Treasurer

Stephen Rodin

43 2014 General Counsel, Secretary

Clive Meanwell

61 2018 Chief Innovation Officer

Alexander Denner

49 2016 Independent Director

Geno Germano

58 2017 Independent Director

John Kelly

76 2011 Independent Director

Paris Panayiotopoulos

45 2017 Independent Director

Sarah Schlesinger

59 2018 Independent Director

Krishna Gorti

2016 IR Contact Officer

Biographies

Name Description

Mark Timney

Mr. Mark Timney is Chief Executive Officer, Director of the company. Mr. Timney has been a director and our chief executive office since December 2018. Mr. Timney is a healthcare leader with over 25 years of biopharmaceutical industry experience in multi-national companies. At Merck & Co, Mr. Timney led organizations of increasing importance and size, including president US, president Japan and president of global primary care. In these roles, he launched multiple products, many in the cardiovascular therapeutic area, led large organizations of up to 8,000 employees, and was involved in a number of important strategic transactions. After leaving Merck, Mr. Timney served as the CEO of Purdue Pharmaceuticals from 2014 to 2017 and, most recently, formed a company advising healthcare companies from 2017 to 2018. Before joining Merck, he spent 8 years working at numerous multinational pharmaceutical companies, including Zeneca Group, ICI Pharmaceuticals and Roussel Labs. Mark received a bachelor’s degree in Sports Studies (majoring in Marketing) from Newcastle Polytechnic (now Northumbria University) in Newcastle in the United Kingdom.

Christopher Visioli

Mr. Christopher J. Visioli is Chief Financial Officer, Treasurer of the Company. He has been our chief financial officer and treasurer since March 2018. He previously served as our senior vice president, financial strategy from January 2015 to March 2018 and our vice president, cardiovascular care from January 2013 to December 2014. Mr. Visioli joined us in June 2003 and has worked in a variety of leadership roles in the organization, including finance, business development, investor relations, strategy, planning, and business leadership of the cardiovascular care unit. He has led many efforts in the organization to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Prior to joining us and before going to business school, Mr. Visioli was a management consultant for Ernst & Young LLP. Mr. Visioli received a BS in electrical engineering from Cornell University and an MBA from Columbia Business School.

Stephen Rodin

Mr. Stephen M. Rodin, J.D., is General Counsel, Secretary of the Company. He has been our general counsel and secretary since March 2014. He also served as our deputy general counsel from March 2010 to March 2014 and associate general counsel from October 2007 to March 2010. Prior to October 2007, Mr. Rodin was an attorney at the law firm of Proskauer Rose LLP in New York where his practice focused on corporate, commercial and securities law. Mr. Rodin received an A.B. from Georgetown University and a J.D. from Vanderbilt University Law School.

Clive Meanwell

Dr. Clive A. Meanwell, M.D. Ph.D., is Chief Innovation Officer of the company. He is a founder and has been a director since 1996. Since December 2018, Dr. Meanwell has served as our chief innovation officer. Prior to December 2018, he served as our chief executive officer since February 2012, our chief executive officer and president from October 2009 to February 2012, our chief executive officer from August 2004 to October 2009, as our president from August 2004 to December 2004, our executive chairman from September 2001 to August 2004 and our chief executive officer and president from 1996 to September 2001. Dr. Meanwell was also chairman of our board from September 2001 to August 2015. Dr. Meanwell is the vice chairman of BB Biotech, a Swiss investment corporation. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. Dr. Meanwell received an M.D. (M.B. Ch.B.) and a Ph.D. (M.D.) from the University of Birmingham, United Kingdom.

Alexander Denner

Dr. Alexander J. Denner, Ph.D., is Independent Director of the Company. He has been a director since February 2016 and chairman of the board since June 2018. Dr. Denner is the founding partner and chief investment officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. From 2006 to 2011, Dr. Denner served as a senior managing director at Icahn Capital, an entity through which Carl Icahn conducts his investment activities. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. Dr. Denner currently serves as a director of Biogen Inc., where he is also the chairperson of Biogen's nominating and governance committee and a member of the finance committee. Dr. Denner also previously served as a director of ARIAD Pharmaceuticals, Inc., where he also served as chairman, Amylin Pharmaceuticals, Inc., Bioverativ Inc., Enzon Pharmaceuticals, Inc., ImClone Systems Incorporated where he also served as chairman of the executive committee and VIVUS, Inc. Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil. and Ph.D. degrees from Yale University.

Geno Germano

Mr. Geno J. Germano is Independent Director of the company. He has been a director since November 2017. Since August 2018 Mr. Germano serves as the chief executive officer and president of Elucida Oncology, Inc. From June 2016 to March 2017, Mr. Germano served as president of Intrexon Corporation, a leader in synthetic biology. He previously held the position of group president of the Global Innovative Pharma Business of Pfizer, Inc., where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates. Mr. Germano was also co-chair of Pfizer’s Portfolio Strategy and Investment Committee and, prior to that, president and general manager of Pfizer’s Specialty Care and Oncology business units. Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals, including president of Wyeth U.S., where he was responsible for the delivery of operational results across four business units, as well as president of its Global Pharmaceutical and Women’s Healthcare Business. Mr. Germano has been a member of the Group of Fifty (G50) and served on the board of the Biotechnology Innovation Organization, where he was a member of the executive committee and chaired the International Committee. He serves on the advisory board of the Healthcare Businesswomen’s Association and was a trustee of the Albany College of Pharmacy from October 2008 to October 2017. Mr. Germano is currently a director of Sage Therapeutics, where he is also the chair of their nominating and governance committee, and was formerly a director of Zoetis Inc. and Bioverativ Inc.

John Kelly

Mr. John C. Kelly is Independent Director of the Company. He has been a director since April 2011, and served as our lead director from May 2015 to August 2015. From October 2009 to February 2010, Mr. Kelly served as senior vice president, finance of Pfizer Inc., or Pfizer. From March 2008 to October 2009, Mr. Kelly served as vice president and controller at Wyeth and from June 2002 to March 2008, he served as vice president, financial operations of Wyeth. Prior to joining Wyeth in 2002, he spent more than 35 years in public accounting at Arthur Andersen in various leadership capacities, including as the partner in charge of audit and business consulting practices in the New York metropolitan area. Mr. Kelly previously served as a director of C.R. Bard, Inc., a medical device company, and a subsidiary of Horizon Blue Cross Blue Shield of New Jersey. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. Mr. Kelly received a B.S. in business administration and an M.B.A. in international finance from Seton Hall University.

Paris Panayiotopoulos

Mr. Paris Panayiotopoulos serves as Independent Director of the Company. Mr. Panayiotopoulos has been a director since March 2017. Mr. Panayiotopoulos is a managing director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus Ventures LLC in December of 2018. Mr. Panayiotopoulos was an operating partner working with Clarus from March 2018 to December 2018. In addition, Mr. Panayiotopoulos serves as the executive chairman of Genevant Sciences. From 2016 to 2017, Mr. Panayiotopoulos was President and Chief Executive Officer and a member of the Board of Directors of Ariad Pharmaceuticals Inc. From 2013 through 2015, Mr. Panayiotopoulos served as President of EMD Serono, Inc., a subsidiary of pharmaceutical company Merck KGaA, Darmstadt, Germany. Prior to being appointed President of EMD Serono, Mr. Panayiotopoulos held positions of increasing responsibility within Merck KGaA, serving as President of Merck Serono, Tokyo, Japan, from 2012 through 2013; Global Chief of Staff for the CEO in Geneva, Switzerland, from 2011 through 2012; Head of Western Europe for the fertility and endocrinology franchises, in 2011; Global Director of the neurology franchise, from 2007 through 2011; and Global Strategy and Business Intelligence Director from 2004 through 2007. Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004. While at Merck KGaA, Mr. Panayiotopoulos led multiple partnerships, including those with Pfizer Inc., Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co. Ltd. and Incyte Corporation and served on the board of directors of BIO. Mr. Panayiotopoulos currently serves on the boards of Corbus Pharmaceuticals and Anthos Therapeutics LLC. Mr. Panayiotopoulos holds a combined B.Sc. in Chemistry and Management Studies from University College London and a M.Sc. in Marketing and Product Management from Cranfield Business School in the United Kingdom.

Sarah Schlesinger

Dr. Sarah J. Schlesinger is Independent Director of the company. She has been a director since February 2018. Dr. Schlesinger has spent more than 20 years working in the field of cellular immunity. She is currently the Chair of The Rockefeller University Hospital’s Institutional Review Board (IRB) and Senior Physician and Associate Professor of Clinical Investigation at The Rockefeller University. Prior to becoming Chair of the hospital’s IRB, Dr. Schlesinger served as Clinical Director of the Laboratory of Molecular Immunology and Clinical Director of The Laboratory of Cellular Immunology and Physiology - the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. Before joining The Rockefeller University in 2003, Dr. Schlesinger was a scientist at the International AIDS Vaccine Initiative in New York City from 2002 to 2003, and a Research Physician/Pathologist at the Division of Retrovirology at the Walter Reed Army Institute of Research from 1996 to 2002. Dr. Schlesinger trained in Surgery at the Albert Einstein College of Medicine and began her career in pathology at Georgetown University in Washington, DC, and hospitals in New York including Buffalo General, Hospital New York and the Manhattan Eye, Ear and Throat Hospital. Dr. Schlesinger leads clinical trials and also chairs the research education and training committee of the Center for Clinical and Translational Science at The Rockefeller University Hospital. She is co-director of Rockefeller’s Clinical Scholars program and the Certificate in Clinical and Translational Sciences program. Widely published in her field, Dr. Schlesinger has been recognized with numerous awards for her research and teaching. She is also a member of numerous, prominent medical societies, including the United States and Canadian Academy of Pathology, the American Association for the Advancement of Science and the College of American Pathologists.

Krishna Gorti

Basic Compensation

Name Fiscal Year Total

Mark Timney

8,724,040

Christopher Visioli

2,096,760

Stephen Rodin

2,295,070

Clive Meanwell

8,836,960

Alexander Denner

345,812

Geno Germano

271,778

John Kelly

344,025

Paris Panayiotopoulos

328,472

Sarah Schlesinger

634,098

Krishna Gorti

--
As Of  31 Dec 2018